# Orion Pharma account plan

> Orion is a Finnish pharmaceutical group in human and veterinary medicines and APIs: EUR 1,889.5 million FY2025 net sales, about 4,000 people.

## At a glance

Orion Corporation, headquartered in Espoo and listed on Nasdaq Helsinki, develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients, with R&D focused on oncology and pain. It sells in over one hundred countries through its own network in Europe and six Asia-Pacific countries and through partners elsewhere, and runs eight production sites (six in Finland, one in France, one in Belgium). FY2025 net sales rose 22.5% to EUR 1,889.5 million and operating profit 51.6% to EUR 631.6 million, driven by royalties on the prostate cancer drug Nubeqa® partnered with Bayer. Personnel was 4,029 at year-end 2025. A shares carry 20 votes and B shares one vote.

## Business units

- **Innovative Medicines** (EUR 812.7 million, 43% of FY2025 net sales): Patent-protected medicines in oncology and pain, led by Nubeqa® (darolutamide), sold by Bayer with Orion earning royalties and supplying the product; Nubeqa® was EUR 609.8 million in 2025 (+65.6%). It became Orion's biggest division in 2026, with 9M sales of EUR 675.6 million (+62.5%). Led by Berkeley Vincent (EVP Innovative Medicines from April 2026), with Outi Vaarala as EVP R&D.
- **Generics and Consumer Health** (EUR 552.8 million, 29% of FY2025 net sales): Generic prescription medicines and consumer health products, strongest in Finland, the Baltics and Scandinavia, plus value-added generics for European hospitals. Sales grew 4.6% in 2025 but fell 1.0% over 9M 2026. From 1 January 2027 it moves under Juhani Kankaanpää's Global Operations as Satu Ahomäki leaves.
- **Branded Products** (EUR 314.6 million, 17% of FY2025 net sales): In-house developed brands in Respiratory (the Easyhaler® portfolio), CNS and Women's Health (Divina®), positioned as the platform for growth in Europe and Asia. Grew 9.4% in 2025 and 10.1% over 9M 2026. From 2027 it is led by Henri Salokangas and adds a Europe-wide hospital business.
- **Animal Health** (EUR 140.9 million, 7% of FY2025 net sales): Proprietary and generic products for companion animals and livestock, including sedatives such as Dexdomitor®. Grew 9.9% in 2025 but slipped 1.8% over 9M 2026 on delivery timing and delayed shipments to the Middle East and Africa; the FDA approved Tessie® for dogs in 2026. Led by Niclas Lindstedt.
- **Fermion** (EUR 68.7 million external sales, 4% of FY2025 net sales): Active pharmaceutical ingredients for Orion and other drug makers, plus contract development and manufacturing; it makes key APIs for all divisions. External sales fell 5.0% in 2025 on capacity constraints, then rose 21.5% over 9M 2026. Part of Global Operations under Juhani Kankaanpää; Kim Nylund is Senior Vice President of Fermion.

## Strategic priorities

- **Grow Nubeqa® with Bayer**: Nubeqa® royalties reached the highest tier in Q2 2026 and now track Bayer's market sales; Orion estimates its Nubeqa net sales could exceed EUR 1 billion by the end of the decade, relying on the 2033 basic patent.
- **Build the innovative pipeline**: Advance ODM-212 (TEAD inhibitor), with Phase 2 readout expected in late 2027 and Phase 3 run by Orion itself, and the first biologic ODM-216, which entered Phase 1 in September 2026.
- **Geographic expansion**: Strengthen Europe, expand in Asia Pacific including Japan, and establish US R&D and commercial operations, starting with a Boston team of "tens of people".
- **Sharper commercial organisation**: From 1 January 2027 a new International Commercial Operations under Hao Pan covers all ex-US commercial activity, while generics move under Global Operations.
- **2024-2028 financial targets**: Net sales CAGR of at least 8%, operating profit growing faster than sales, equity ratio of at least 50% and ROE of 25% or higher.

## Latest results

In January-September 2026 net sales rose 24.1% to EUR 1,481.5 million and operating profit 65.2% to EUR 501.2 million. Q3 alone brought net sales of EUR 542.2 million (+28.1%) and operating profit of EUR 209.9 million (38.7% margin), with Nubeqa® at EUR 279.9 million as the highest royalty tier applied all quarter. Branded Products grew 10.8% in Q3 while Generics and Consumer Health fell 3.4%. On 20 October 2026 Orion raised its 2026 outlook to net sales of EUR 2,070-2,140 million and operating profit of EUR 730-790 million, excluding material milestones. It had a net cash position at 30 September 2026 (gearing -1.3%).

## Investments and deals

- **R&D spending**: R&D expenses were EUR 210.4 million in 2025 (11.1% of net sales) and EUR 168.2 million in 9M 2026 (+20.3%), with all projects running at once.
- **Darolutamide supply capacity**: Part of the darolutamide API is moving to a European contract manufacturer and a US-based contract manufacturer to manage supplier risk; tablets remain made in Orion's own plant.
- **Cambridge R&D centre**: A new R&D centre in Cambridge, UK, focused on biologics and large molecules, part of 2025 capex of EUR 112.9 million.
- **Licensing deals**: Biosimilar licences from Shilpa (IV nivolumab) and Qilu (IV pembrolizumab) for Europe, with launches expected in the early 2030s, and the APORON® apomorphine spray licence from Criceto.
- **MSD opevesostat licence**: MSD holds a global licence for opevesostat, with Orion eligible for up to USD 30 million development, USD 625 million regulatory and USD 975 million sales milestones plus royalties.

## Challenges and risks

- **Dependence on Nubeqa® and Bayer**: Bayer represented about EUR 808.9 million of 2025 revenue, and the predictability of Nubeqa® royalties is a stated risk.
- **US pharmaceutical tariffs**: Tariffs on Nubeqa were expected from October 2026, minor for Q4, with a bigger impact expected in 2027.
- **Supply-chain and production risk**: Risks include disruption of own production and supplier dependence, illustrated by the July 2026 water damage at Fermion's Hanko plant, which will weigh on Fermion's Q4 external sales.
- **Generics price competition**: Tougher price competition and regulatory change weigh on generics, which fell 3.4% in Q3 2026 on many small declines.
- **R&D timing and failures**: Partner Tenax's LEVEL Phase 3 trial of oral levosimendan missed its endpoints in 2026, and ODM-105 was terminated after failing Phase 2.

## What leadership says

> "We have not changed our strategy. On the contrary, our strategy has become a necessity." — Liisa Hurme, President and CEO, Q3 2026 conference call, 28 October 2026

> "we have a potentially best-in-class TEAD inhibitor in our hands" — Liisa Hurme, President and CEO, On ODM-212, half-year 2026 conference call, 17 July 2026

> "almost half of Orion's revenue comes from innovative medicines after the first nine months" — Liisa Hurme, President and CEO, Q3 2026 conference call, 28 October 2026

> "when you build resilience, there is, of course, some price to that" — René Lindell, CFO, On dual-sourcing darolutamide API, Q3 2026 conference call, 28 October 2026


## Where a supplier can help

- **API capacity and contract manufacturing**: Tied to the darolutamide supply investment and supply-chain risk: CDMOs, quality and supplier-qualification services help Orion add resilient capacity.
- **US build-up support**: Tied to the geographic expansion priority: recruiting, regulatory, medical affairs and market access services for the Boston team preparing ODM-212 Phase 3.
- **Clinical development capacity**: Tied to the pipeline priority and rising R&D spend: CROs, trial sites and biologics development partners for ODM-212, ODM-216 and the Cambridge centre.
- **Commercial operations reorganisation**: Tied to the new International Commercial Operations from 2027: CRM, sales analytics and commercial excellence tools for a unified ex-US organisation.
- **Generics cost and service efficiency**: Tied to generics price competition: supply planning, procurement and logistics tools for a business management calls "really about supply, price, and service level".

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Orion Corporation Financial Statement Documents 2025](https://www.orionpharma.com/492ebb/globalassets/investors/hallinnointi/yhtiokokous/yhtiokokous-2026/orion-financial-statement-documents-2025.pdf)

Annual report · 2026-02-27

- Orion Corporation is a Finnish pharmaceutical group (HQ Espoo, A and B shares on Nasdaq Helsinki) that develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients; core R&D therapy areas are oncology and pain.
- FY2025 net sales rose 22.5% to EUR 1,889.5 million (2024: 1,542.4), of which milestones EUR 183.4 million; operating profit rose 51.6% to EUR 631.6 million (33.4% margin); profit for the period EUR 500.3 million; basic EPS EUR 3.56; proposed dividend EUR 1.80 per share.
- Nubeqa® (darolutamide, prostate cancer, partnered with Bayer) is the engine: EUR 609.8 million in 2025 (+65.6%), of which royalties EUR 432.5 million, plus a EUR 180 million milestone; Orion estimates its Nubeqa net sales could exceed EUR 1 billion by the end of the decade.
- Five business divisions: Innovative Medicines EUR 812.7 million (43% of net sales), Generics and Consumer Health EUR 552.8 million (29%), Branded Products EUR 314.6 million (17%), Animal Health EUR 140.9 million (7%), Fermion (APIs) EUR 68.7 million (4%).
- Geography: Other Europe EUR 530.2 million, North America EUR 481.1 million, Finland EUR 365.6 million, Rest of the World EUR 323.0 million, Scandinavia EUR 189.6 million; one major customer (Bayer) represented about EUR 808.9 million of revenue.
- Strategy: build a customer-driven portfolio, expand geographically (strengthen Europe, expand in Asia Pacific including Japan, establish US R&D and commercial operations) and develop growth enablers; 2024-2028 targets are net sales CAGR of at least 8%, operating profit growing faster than sales, equity ratio of at least 50%, ROE of 25% or higher.
- R&D spend EUR 210.4 million (11.1% of sales) and capex EUR 112.9 million; new R&D centre in Cambridge, UK; MSD licence on opevesostat worth up to USD 30 million development, USD 625 million regulatory and USD 975 million sales milestones; ODM-212 (TEAD inhibitor) entered Phase 2.
- 2026 outlook (14 January 2026): net sales EUR 1,900-2,100 million and operating profit EUR 550-750 million, with no material milestones assumed; key risks are US pharma tariffs, Nubeqa royalty predictability, supply-chain disruption, price competition and R&D timing.
- About 4,000 people (4,029 at year end); 8 production sites (six in Finland, one in France, one in Belgium); CEO Liisa Hurme, CFO René Lindell, Chair Veli-Matti Mattila.

### [Orion Group Half-Year Financial Report January-June 2026](https://www.orionpharma.com/4a0728/globalassets/investors/reports-and-presentations/2026/orion-half-year-financial-report-2026.pdf)

Interim report · 2026-07-17

- H1 2026 net sales EUR 939.3 million (+21.8% vs 771.0) and operating profit EUR 291.3 million (+59.6%); Q2 alone net sales EUR 521.6 million (+25.2%) and operating profit EUR 176.6 million (+68.8%, 33.9% margin).
- Nubeqa® drove growth: H1 EUR 381.8 million (+64.9%), of which royalties EUR 267.4 million (+79.0%); the highest tier of the annual Nubeqa® royalty scale was reached in Q2.
- Innovative Medicines H1 EUR 392.0 million (+60.3%); Branded Products EUR 172.9 million (+9.9%, Divina® +47.6%); Generics and Consumer Health EUR 267.4 million (+0.3%); Animal Health EUR 70.2 million (-2.4%); Fermion EUR 36.8 million (+17.1%).
- Outlook narrowed upward on 17 July 2026: net sales EUR 2,000-2,100 million (was 1,950-2,100) and operating profit EUR 650-750 million (was 600-750).
- Pipeline: ODM-212 (TEAD inhibitor) started TEADCO Phase 1b/2, presented Phase 1 TEADES data at ASCO and got orphan designations in the US and EU; FDA approved Animal Health's Tessie® for dogs, partner sales expected mid-2027.
- Cash flow from operations EUR 311.8 million (+98.7%) after receipt of the EUR 180 million Nubeqa® milestone; loans of EUR 161.0 million repaid; gearing 0.2%, equity ratio 67.9%.
- Berkeley Vincent appointed EVP Innovative Medicines (from April 2026); Shilpa licence for an IV nivolumab biosimilar in Europe (launch expected early 2030s); water damage at Fermion's Hanko plant in July, not expected to be material.

### [Orion Group Interim Report January-September 2026](https://www.orionpharma.com/4aac8d/globalassets/investors/reports-and-presentations/2026/orion-interim-report-q3-2026.pdf)

Interim report · 2026-10-28

- Q3 2026 net sales EUR 542.2 million (+28.1%) and operating profit EUR 209.9 million (+73.5%, 38.7% margin); January-September net sales EUR 1,481.5 million (+24.1%) and operating profit EUR 501.2 million (+65.2%).
- Nubeqa® Q3 EUR 279.9 million (+69.0%), royalties EUR 222.3 million (+88.1%) with the highest royalty tier applying all quarter; 9M Nubeqa® EUR 661.7 million.
- Outlook upgraded on 20 October 2026: net sales EUR 2,070-2,140 million and operating profit EUR 730-790 million (previously 2,000-2,100 and 650-750).
- Branded Products Q3 +10.8% (Women's Health +45.5%); Generics and Consumer Health -3.4%; Animal Health -0.3%; Fermion +31.6% on contract development and manufacturing.
- Darolutamide API capacity expanded through a European contract manufacturer and a US-based contract manufacturer.
- Pipeline: first biologic, bispecific antibody ODM-216, entered Phase 1 (BICIDES); DASL-HiCaP interim Phase 3 data showed a 58% reduction in risk of metastasis or death; Tenax's LEVEL Phase 3 missed its endpoints.
- Qilu licence (October) for an IV pembrolizumab biosimilar in Europe, launch expected early 2030s.
- Executive Team changes from 1 January 2027: new International Commercial Operations led by Hao Pan as EVP and Chief Commercial Officer; Henri Salokangas EVP Branded Products; Satu Ahomäki leaving; Juhani Kankaanpää adds Generics and Consumer Health to Global Operations.
- Net cash position (gearing -1.3%); 500,000 B shares bought back for about EUR 40.5 million for incentive plans.

### [Orion Q3 2026 conference call and webcast (transcript)](https://www.inderes.fi/en/transcripts?transcript=orion-webcast-q326)

Executive talk · Liisa Hurme, President and CEO (with René Lindell, CFO) · 2026-10-28

- CEO Liisa Hurme and CFO René Lindell presented Q3 2026 (net sales EUR 542 million, +28%; operating profit EUR 210 million) and the raised outlook of EUR 2,070-2,140 million sales and EUR 730-790 million operating profit.
- Hurme: almost half of Orion's revenue after nine months comes from Innovative Medicines (Nubeqa® royalties and product sales); the maximum royalty rate was reached in Q2, so Q4 royalties now track Bayer's in-market sales.
- The strategy launched in 2023 has "become a necessity": Orion is moving to a next stage that sharpens focus on strategic assets, with a new international commercial organisation under Hao Pan and US operations under Berkeley Vincent.
- Branded Products gains a Europe-wide hospital business (Simdax, Dexdor, biosimilars, recombinant albumin); generics, "really about supply, price, and service level", moves under Global Operations.
- Darolutamide API is being dual-sourced (Hong Kong, Germany, and a US site) to manage supplier risk; the gross-margin impact "will be marginal" (Lindell). Tablets stay in Orion's own plant.
- Pipeline: first biologic ODM-216 in Phase 1, possibly another Phase 1 programme this year; Orion plans to run ODM-212 Phase 3 itself; it would opt in to DASL-HiCaP if Bayer files.
- Bayer expects Nubeqa to be its biggest product (around EUR 5 billion, Hurme); Orion relies on the 2033 basic patent. AI has helped halve discovery and research time.
- US tariffs on Nubeqa expected from October, minor for Q4; animal health shipments to the Middle East and Africa delayed by geopolitics.

### [Orion Half-Year 2026 conference call and webcast (transcript)](https://www.inderes.fi/en/transcripts?transcript=orion-webcast-q226)

Executive talk · Liisa Hurme, President and CEO (with René Lindell, CFO) · 2026-07-17

- CEO Liisa Hurme and CFO René Lindell presented H1 2026 on 17 July 2026: Q2 net sales EUR 522 million (+25%) and operating profit EUR 177 million (+69%, 34% margin); outlook raised to EUR 2-2.1 billion sales and EUR 650-750 million operating profit.
- Hurme: Innovative Medicines is now Orion's biggest division, ahead of Generics and Branded Products; Nubeqa royalty income is "very back-end loaded" within a year and the top royalty tier was reached in Q2.
- ODM-212 (TEAD inhibitor) is pitched as "potentially best-in-class": Phase 2 in mesothelioma and EHE reads out in late 2027, the Phase 1b/2 combination study in 2029; Orion plans to run Phase 3 itself with no partner.
- Divina® grows around 40% a year, helped partly by competitor HRT stock-outs in the Nordics; Fermion's Hanko water damage is a matter of "rather weeks than months".
- US build-up: a Boston team in clinical, regulatory and R&D plus a new US commercial head; "tens of people, not hundreds", with a real cost step only near launch.
- Lindell: US tariffs on European innovative pharma assumed from October, small in 2026 and bigger in 2027; the gross margin rise comes mainly from Nubeqa royalties.
- Excluding Simdax and Dexdor, generics grew 2%; FDA approved Tessie® for dogs, partner launch mid-2027.

## Questions about Orion Pharma

### What does Orion Corporation do?

Orion is a Finnish pharmaceutical company that develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients, with R&D in oncology and pain.

### What is Orion's revenue?

FY2025 net sales were EUR 1,889.5 million (+22.5%) and operating profit EUR 631.6 million. The 2026 outlook is net sales of EUR 2,070-2,140 million and operating profit of EUR 730-790 million.

### How many employees does Orion have?

Orion had 4,029 people at the end of 2025; the average headcount in January-September 2026 was 4,174.

### Who leads Orion?

Liisa Hurme is President and CEO, René Lindell is CFO, and Veli-Matti Mattila chairs the Board.

### What is Orion's strategy?

Build a customer-driven portfolio, expand geographically in Europe, Asia Pacific and the US, and develop growth enablers, targeting net sales CAGR of at least 8% over 2024-2028.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
